Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
Kerecis has been recognized by MedTech Outlook Magazine as the exclusive recipient of “Top 10 Surgical Solution Companies - 2020,” based on our proprietary methodology, reflecting its position in the industry. This profile has been developed by the MedTech Outlook research and editorial team based on insights from an interview with Gudmundur Fertram Sigurjonsson, Founder, President and CEO.
Gudmundur Fertram Sigurjonsson, Founder, President and CEOThey are non-allergenic, and there are no cultural or religious barriers to usage. The Kerecis products can be stored at room temperature for up to three years. Preparation is simple; the products only need to be rehydrated in saline water. The fish skin’s large, thick sheets are easy to use, mesh-like human skin, and are strong enough to support sutures and staples.![]()
Surgeons and wound care center doctors are constantly amazed at how Kerecis helps even their most complicated cases heal
Company
Kerecis
Management
Gudmundur Fertram Sigurjonsson, Founder, President and CEO
Description
Develops and produces fish-skin, skin-substitute products that support the
body’s ability to regenerate tissues. The products are used to treat wounds and burns.
Sito Web:
mythras.it
Amministratore:
Roberto Livio Mastronardi, co-fondatore
Descrizione:
Mythras è un team di tecnici specializzati nell'assistenza tecnica su strumentazione IVD, esperti nell'aiutare i responsabili di laboratorio a garantire la precisione, l'accuratezza e la conformità dei loro strumenti. È la scelta ideale per numerosi clienti e distributori, al servizio delle loro complesse esigenze di assistenza tecnica e ricondizionamento della strumentazione IVD.
Citazione:
“Siamo certificati ISO 9001:2015 per l'assistenza tecnica e il ricondizionamento della strumentazione analitica IVD.”
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Medical fish skin company Kerecis has launched the MariGen Shield – a solution that combines the company’s fish-skin graft and a silicone contact layer to treat chronic and complex wounds. The latest product is fenestrated to enable proper drainage of wounds. It creates an ideal environment for wound management and ensures optimal moisture levels that promote effective healing.
The integrated, overlapping silicone contact layer anchors the round graft in position, helping to safeguard the granulating wound and the fish-skin graft following the application of a protective cover dressing.
Kerecis is offering MariGen Shield in round grafts of 20mm and 30mm for application to foot wounds.
Kerecis founder and CEO Fertram Sigurjonsson said: “Until now, the application of the Kerecis fish-skin graft has required three components: the fish skin itself, a contact layer and a cover dressing to regulate the moisture level on the wound.”
“By integrating the contact layer with the fish skin, the application becomes faster and easier and the inventory needs at the healthcare facility simpler.”
Additionally, the company has disclosed the findings of a clinical trial that evaluated the efficacy of Kerecis fish-skin grafts in comparison to a standard of care for the management of diabetic foot ulcers.
The findings along with the new product were announced at the Symposium on Advanced Wound Care event in Maryland, US.
The multicentre and comparative study demonstrated that the MariGen outperformed Fibracol therapy by nearly doubling the healing rate of non-responsive, chronic diabetic foot ulcers.
The trial was carried out across 16 centres in the US, involving a total of 102 patients between June 2019 and January last year.